Literature DB >> 17137333

Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients.

Yuko Ogata1, Carrie J Heppelmann, Carrie J Heppelmann, M Cristine Charlesworth, Benjamin J Madden, Melinda N Miller, Kimberly R Kalli, William A Cliby, H Robert Bergen, Diana A Saggese, David C Muddiman.   

Abstract

We evaluated the differentially expressed proteins in the plasma of ovarian cancer (OVC) patients using 2-D SDS-polyacrylamide gel electrophoresis (SDS-PAGE) with post-translational modification (PTM) specific stains after the removal of six high-abundance proteins. The pooled plasma from patients with stage III or IV OVC was compared to a pooled postmenopausal age-matched control. Several proteins were identified as differentially expressed in the plasma of OVC patients. Among them, the phosphorylated fibrinogen-alpha-chain isoform (containing fibrinopeptide-A) was found to be up-regulated. Previously in our laboratory, phosphorylated fibrinopeptide-A was found to be up-regulated in the low molecular weight fraction of serum derived from OVC patients. We examined the levels of phosphorylated fibrinogen-alpha-chain in each patient that constituted the pooled plasma using Western blot, mass spectrometry (MS), and PTM specific stains. Phosphoprotein bands containing fibrinogen-alpha-chain fragments showed up-regulation in all OVC patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17137333     DOI: 10.1021/pr060344+

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  17 in total

1.  Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.

Authors:  Madhavi A Jadhav; Giulia Isetti; Toni A Trumbo; Muriel C Maurer
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

2.  Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis.

Authors:  John D Andersen; Kristin L M Boylan; Feifei S Xue; Lorraine B Anderson; Bruce A Witthuhn; Todd W Markowski; Leeann Higgins; Amy P N Skubitz
Journal:  Electrophoresis       Date:  2010-01       Impact factor: 3.535

Review 3.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

4.  In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans.

Authors:  Angelito I Nepomuceno; Huanjie Shao; Kai Jing; Yibao Ma; James N Petitte; Michael O Idowu; David C Muddiman; Xianjun Fang; Adam M Hawkridge
Journal:  Anal Bioanal Chem       Date:  2015-07-10       Impact factor: 4.142

5.  Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Authors:  Russell J Schilder; Harsh B Pathak; Anna E Lokshin; Robert W Holloway; Ronald D Alvarez; Carol Aghajanian; Hua Min; Karthik Devarajan; Eric Ross; Charles W Drescher; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2009-01-21       Impact factor: 5.482

6.  Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry.

Authors:  D Keith Williams; David C Muddiman
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

7.  Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma.

Authors:  Xing-chen Peng; Feng-ming Gong; Yu-wei Zhao; Liang-xue Zhou; Ying-wei Xie; Hong-li Liao; Hong-jun Lin; Zhi-yong Li; Ming-hai Tang; Ai-ping Tong
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

8.  Proteomics and mass spectrometry for cancer biomarker discovery.

Authors:  Ming Lu; Kym F Faull; Julian P Whitelegge; Jianbo He; Dejun Shen; Romaine E Saxton; Helena R Chang
Journal:  Biomark Insights       Date:  2007-10-03

Review 9.  Ectokinases as novel cancer markers and drug targets in cancer therapy.

Authors:  Garif Yalak; Viola Vogel
Journal:  Cancer Med       Date:  2014-12-14       Impact factor: 4.452

10.  Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.

Authors:  K S Okunade; O Dawodu; M Adenekan; C M Nwogu; O Awofeso; A O Ugwu; O Salako; S John-Olabode; O F Olowoselu; R I Anorlu
Journal:  Niger J Clin Pract       Date:  2020-08       Impact factor: 0.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.